These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 785946)

  • 1. Synergistic effect of alloantibodies or F(ab')2 and prednisone on murine split heart allograft survival.
    Schilling W; Svehag SE
    Acta Pathol Microbiol Scand C; 1976 Aug; 84(4):325-32. PubMed ID: 785946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism between alloantibodies or F(ab') 2 and prednisone in the survival of murine split heart allografts.
    Svehag SE; Schilling W
    Transplantation; 1973 Mar; 15(3):344-6. PubMed ID: 4576044
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged survival of renal allografts in outbred rabbits treated with donor specific F(ab')2 alloantibody.
    Sutherland DE; Howard RJ; Dombrovskis S; Najarian JS
    Ann Surg; 1974 Dec; 180(6):857-63. PubMed ID: 4611361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged survival of corneal allografts incubated in alloantibody fragments.
    Gebhardt BM; Varnell ED; Kaufman HE
    Transplantation; 1999 Feb; 67(4):594-9. PubMed ID: 10071033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive enhancement of mouse skin allografts by alloantibodies is Fc dependent.
    Capel PJ; Tamboer WP; de Waal RM; Jansen JL; Koene RA
    J Immunol; 1979 Feb; 122(2):421-5. PubMed ID: 368240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin-145-2C11-F(ab')2 promotes peripheral tolerance and reduces chronic vascular disease in mouse cardiac allografts.
    Han WR; Murray-Segal LJ; Gershenzon A; Zhang JG; Hodder AN; Pietersz GA; Mottram PL
    Transpl Immunol; 1999 Dec; 7(4):207-13. PubMed ID: 10638833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological enhancement of a murine tumor allograft by passive alloantibody IgG and F(ab')2.
    Kaliss N; Sinclair NR; Cantrell JL
    Eur J Immunol; 1976 Jan; 6(1):38-42. PubMed ID: 971718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperimmune F(ab') 2 antibody: role in canine hyperacute renal allograft rejection.
    Habal MB; Kobayashi K; Busch GJ; Birtch AG
    J Surg Res; 1972 Nov; 13(5):228-31. PubMed ID: 4117988
    [No Abstract]   [Full Text] [Related]  

  • 9. Passive enhancement of mouse tumor allografts by alloantibodies is Fc-dependent.
    de Waal RM; Cornelissen IM; Capel PJ; Koene RA
    J Immunol; 1979 Sep; 123(3):1353-5. PubMed ID: 469254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protective effect of F(ab') 2 and succinylated IgG in the early treatment of hyperacute rejection in the primate.
    Habal MB; Carpenter CB; Kobayashi K; Bush GJ; Misra M; Birtch AG
    Transplant Proc; 1973 Mar; 5(1):601-6. PubMed ID: 4633093
    [No Abstract]   [Full Text] [Related]  

  • 11. A quantitative comparison of whole antibody and F(ab')2 in kidney allograft enhancement.
    Winearls CG; Fabre JW; Millard PR; Morris PJ
    Transplantation; 1979 Jul; 28(1):36-9. PubMed ID: 377591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of an anti-interleukin 2 receptor monoclonal antibody in rat recipients of a heart allograft, and its use as a rejection marker in gamma scintigraphy.
    Thedrez P; Paineau J; Jacques Y; Chatal JF; Pelegrin A; Bouchaud C; Soulillou JP
    Transplantation; 1989 Sep; 48(3):367-71. PubMed ID: 2675394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of human F(ab') 2 fragments as blocking agents in the mixed lymphocyte reaction.
    Hornung MO; Layne E; McDonald JC
    J Immunol; 1971 Oct; 107(4):979-84. PubMed ID: 4999263
    [No Abstract]   [Full Text] [Related]  

  • 15. Passive enhancement of canine renal allografts with polyspecific F(ab')2 fragments.
    Wren SF; Martins AC; Von Haefen U; Busch GJ; Katske GE; Koppenheffer TL; Shaipanich T; Wilson RE
    Surgery; 1974 Jul; 76(1):112-20. PubMed ID: 4135410
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of antibody reactivity to major histocompatibility complex (MHC) and non-MHC alloantigens on graft endothelial cells in heart allograft rejection.
    Derhaag JG; Duijvestijn AM; Damoiseaux JG; van Breda Vriesman PJ
    Transplantation; 2000 May; 69(9):1899-906. PubMed ID: 10830229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.
    Hirsch R; Bluestone JA; DeNenno L; Gress RE
    Transplantation; 1990 Jun; 49(6):1117-23. PubMed ID: 2141740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of heart and rejection of lymphocyte allografts from the same donor in recipients of donor-specific transfusions.
    Jaskłowska-Englisz M; Olszewski WL; Maksymowicz M; Ziółkowska A
    Ann Transplant; 1998; 3(1):28-33. PubMed ID: 9869895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells.
    Tanaka K; Hancock WW; Osawa H; Stunkel KG; Alberghini TV; Diamantstein T; Tilney NL; Kupiec-Weglinski JW
    J Immunol; 1989 Nov; 143(9):2873-9. PubMed ID: 2530281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of islet allograft survival in mice treated with MHC class I specific F(ab')2 alloantibody.
    Osorio RW; Ascher NL; Melzer JS; Stock PG
    Transplant Proc; 1994 Apr; 26(2):749. PubMed ID: 8171642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.